Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Evusheld

- PMLiVE

Young diabetes patients in England and Wales receive fewer vital checks

Less than a third with type 1 diabetes receive eight of nine recommended care processes

- PMLiVE

NICE recommends Lundbeck’s alcohol dependency drug

NHS patients to have access to Selincro to help control drinking

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

AZ: We have to be able to show mHealth can work

Still room for improvement in mobile health, Andy Jones tells ThinkDigital

- PMLiVE

Iressa blood test nears approval in Europe

Diagnostic for AZ's lung cancer drug is less invasive than current tumour biopsy method

National Institute for Health and Care Excellence NICE logo

Remicade, Humira and Simponi face NICE knock-back

Draft guidance does not recommend the drugs for ulcerative colitis

- PMLiVE

AZ sets up joint lab with Cancer Research UK

Five-year collaboration will drive charity’s research programmes

- PMLiVE

NICE backs Celgene’s Revlimid in rare blood cancer

Patient access scheme sways the HTA body

- PMLiVE

NICE fast-tracks GSK’s skin cancer drug Tafinlar

But only on condition the company cuts its price

- PMLiVE

FDA approves AZ’s opioid-induced constipation drug Movantik

Trials showed positive reactions to the treatment

- PMLiVE

AZ and Lilly set up BACE camp for Alzheimer’s

Lilly will pay AZ up to $500m in development and regulatory costs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links